BAX and melanoma: Our data showed that only LCL-SIM and LCL-SIM + LCL-DMXAA-treated tumors showed a 1.5-fold increase in Bax/Bcl-xL production ratio (Fig. 4E, P < 0.05) indicating that liposomal SIM sensitized melanoma cells to LCL-DMXAA therapy.